中国现代医学杂志2026，Vol.36Issue(4)：1-6,6.DOI:10.3969/j.issn.1005-8982.2026.04.001
吡咯替尼联合曲妥珠单抗、白蛋白结合型紫杉醇治疗Her-2阳性晚期乳腺癌的疗效分析
Efficacy of pyrotinib combined with trastuzumab and albumin-bound paclitaxel for HER2-positive advanced breast cancer
摘要
Abstract
Objective To analyze the effect of pyrotinib(Py)combined with trastuzumab and albumin-bound paclitaxel in patients with human epidermal growth factor receptor 2(HER2)-positive advanced breast cancer.Methods A total of 82 patients with HER2-positive advanced breast cancer admitted to our hospital between January 2019 and January 2024 were selected,and divided into two groups according to different treatment regimens.The control group(n=40)received trastuzumab plus albumin-bound paclitaxel,while the observation group(n=42)received additional Py therapy.The therapeutic effect of the two groups was compared.Results The objective response rate and disease control rate in the observation group were significantly higher than those in the control group(P<0.05).The differences in serum levels of carcinoembryonic antigen,carbohydrate antigen 125,and carbohydrate antigen 153,CD4+and CD8+levels,CD4+/CD8+ratio,Karnofsky Performance Status,and quality of life scale scores before and after treatment were significantly greater in the observation group than in the control group(P<0.05).There was no statistically significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).The survival curve of the observation group was significantly better than that of the control group(P<0.05).Conclusion The addition of pyrotinib to trastuzumab and albumin-bound paclitaxel in the treatment of HER2-positive advanced breast cancer effectively reduces the levels of tumor markers,enhances anti-tumor immunity,and improves quality of life and survival rates,without significantly increasing adverse reactions,demonstrating favorable short-term efficacy and safety.关键词
晚期乳腺癌/吡咯替尼/曲妥珠单抗/白蛋白结合型紫杉醇/人类表皮生长因子受体-2Key words
advanced breast cancer/pyrotinib/trastuzumab/albumin-bound paclitaxel/human epidermal growth factor receptor 2分类
医药卫生引用本文复制引用
姚慰峰,潘德键..吡咯替尼联合曲妥珠单抗、白蛋白结合型紫杉醇治疗Her-2阳性晚期乳腺癌的疗效分析[J].中国现代医学杂志,2026,36(4):1-6,6.基金项目
江苏省科技计划重点研发项目(No:BE2022697) （No:BE2022697）
无锡市科技发展基金指导性计划项目(No:202029) （No:202029）
